2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Peter Riedell, MD, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma.
Peter Riedell, MD, assistant professor of medicine, University of Chicago Medicine, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma (MCL).
The analysis focused on evaluating the effect of time to relapse on OS in adult patients with MCL who were treated with up to 2 lines of rituximab (Rituxan)-based induction therapy, followed by frontline autologous stem cell transplantation (ASCT), according to Riedell. In an effort to include a homogenous population, the analysis only included patients who underwent ASCT within 1 year of their diagnosis, Riedell explains. Patients who were transplanted between 2000 and 2018 were evaluated, Riedell adds.
Primary end points included overall survival (OS) and post-relapse OS, Riedell adds. The dynamic landmark analysis was employed at 6-month intervals to evaluate the effects of relapse on OS while adjusting for pertinent patient- and disease-related variables, Riedell concludes.